Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Procedural Prescription Denials and Risk of Acute Care Utilization and Spending Among Medicaid Patients.
JAMA Netw Open
January 2025
Clinical Product Development, Waymark, San Francisco, California.
Importance: Rising prescription medication costs under Medicaid have led to increased procedural prescription denials by health plans. The effect of unresolved denials on chronic condition exacerbation and subsequent acute care utilization remains unclear.
Objective: To examine whether procedural prescription denials are associated with increased net spending through downstream acute care utilization among Medicaid patients not obtaining prescribed medication following a denial.
ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritis.
Clin Rheumatol
January 2025
Faculty of Medicine, Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey.
Objectives: To determine the features of rheumatoid pulmonary nodules and the factors associated with nodule progression in patients with rheumatoid arthritis.
Methods: Between January 2010 and September 2018, RA patients with at least one chest computed tomography (CT) were included. Two experienced radiologists examined chest CTs.
Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need.
Drugs Aging
January 2025
Department of Dermatology, University of Texas Health Science Center, 7979 Wurzbach Rd, Grossman 3rd FL, San Antonio, TX, 78229, USA.
Chronic itch in older patients is a common problem, with a significant impact on quality of life. Chronic itch in the older population may be attributable to several causes, such as age-related changes, skin conditions, systemic conditions, medications, and psychological conditions. Given the complexity of itch in this population, comorbidities, and polypharmacy in most geriatric patients, treating chronic itch can be challenging for healthcare providers.
View Article and Find Full Text PDFAnti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFPerspectives of People with Type 2 Diabetes Mellitus Towards a Decision Aid Assessing Preferences of Glucose-Lowering Drugs: The Dilemma of Choosing.
Patient Prefer Adherence
January 2025
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Background: Treatment guidelines recommend metformin as initial drug in many people with type 2 diabetes (T2D) and low risk of cardiovascular disease, with the possibility to switch to or add other drug classes. A decision aid (DA) could be useful to incorporate a patient's preferences in the decision of which drug class to choose. We developed such a DA and assessed the perspectives of people with T2D towards its comprehensibility and usability.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!